Company Overview - Baxter International Inc. (BAX) has a market cap of $9.4 billion and specializes in essential hospital products and therapies used in various medical settings [1] - The company is headquartered in Deerfield, Illinois, and its product portfolio includes infusion systems, dialysis equipment, sterile IV solutions, and advanced patient monitoring technologies [1] Market Position - BAX is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the medical instruments and supplies industry [2] - The company's market leadership is supported by demand trends in acute care and chronic therapies, cost-restructuring efforts, and strategic portfolio realignment following divestitures and spinoffs [2] Stock Performance - BAX shares have decreased by 49.9% from their 52-week high of $37.74, reached on March 10, and have declined 22.8% over the past three months, underperforming the Health Care Select Sector SPDR Fund's (XLV) 9.9% return [3] - Year-to-date, BAX shares have dipped 35.2% and have fallen 39% over the past 52 weeks, significantly lagging behind XLV's YTD gains of 11.6% and 8.1% returns over the last year [4] Technical Indicators - BAX has been trading below its 50-day and 200-day moving averages since early April and late March, respectively, confirming a bearish trend [4] Dividend Announcement - The company announced a quarterly cash dividend of $0.01 per share, leading to a 2.8% rise in shares, with the dividend payable on January 2, 2026, to shareholders of record on November 28, 2025 [5] Analyst Sentiment - Wall Street analysts have a cautious outlook on BAX, with a consensus "Hold" rating from 16 analysts and a mean price target of $22.29, indicating a potential upside of 17.9% from current price levels [6]

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant awareness of the issues [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to October 29, 2025, with a deadline for shareholders to register by December 15, 2025 [3][4]. - Shareholders who purchased shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Insights - Baxter International Inc. announced positive data regarding the integration of smart infusion pumps with hospital electronic medical records (EMRs), highlighting improvements in patient safety, clinician productivity, and programming compliance [1] Group 1: Company Impact - The collaboration with The University of Texas Medical Branch (UTMB Health) analyzed over one million infusions, demonstrating the effectiveness of Baxter's Spectrum IQ infusion system [1]

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

Core Insights - Pzena Investment Management's third-quarter 2025 commentary indicates a strong performance in US broad-based indexes driven by optimism about AI and a September rate cut, with the technology sector outperforming value stocks [1] - The Pzena Focused Value strategy returned 1.1% gross and 0.9% net, underperforming the Russell 1000 Value Index which returned 5.3% [1] Company Overview: Baxter International Inc. (NYSE:BAX) - Baxter International Inc. is a healthcare company with a market capitalization of $9.335 billion, and its stock closed at $18.48 per share on December 09, 2025 [2] - The stock experienced a one-month return of -2.89% and a significant decline of 41.42% over the last 52 weeks [2] Performance Analysis - Baxter's disappointing performance in the third quarter was attributed to a voluntary recall of a recent product launch and a slower-than-expected recovery in demand for IV fluids, which were disrupted by Hurricane Helene [3] - Despite these challenges, the Pzena Focused Value Strategy views the stock price reaction as disproportionate and has increased its position in Baxter [3] Hedge Fund Interest - Baxter International Inc. was held by 38 hedge fund portfolios at the end of the third quarter, an increase from 31 in the previous quarter [4] - While Baxter is recognized for its potential, analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4] Market Sentiment - The SCCM Enhanced Equity Income Fund divested its stake in Baxter during Q3 2025, indicating a shift in investment strategy among some funds [5]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Insights - Baxter International Inc. is currently among the Top 15 Lowest P/E Ratios of the S&P 500 for 2025, indicating a potentially undervalued stock [1] - Analysts have a consensus Hold recommendation for Baxter, with a one-year average share price target of $23.80, suggesting an upside potential of 28% [4] Financial Adjustments - Morgan Stanley analyst Patrick Wood has reduced the price target for Baxter from $19 to $15 while maintaining an Underweight rating [1] - Argus Research downgraded Baxter on October 31, citing a significant dividend reduction expected to drive an annual cash flow boost of $300 million or more, aimed at strengthening the balance sheet [3] Market Position and Performance - The company is well-positioned in the medical technology sector due to favorable trends in hospital spending and key product launches [2] - Baxter's stock has faced challenges, declining 36% year to date [4] - Concerns have been raised regarding the weak outlook for Baxter's IV fluid solutions business [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which Baxter was aware of but did not adequately address [5] - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [4][5]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions and risks to patient safety [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [6]. Group 2: Financial Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries related to the Novum LVP but failed to take adequate remedial measures [4]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3]. - The firm encourages anyone with information regarding Baxter's conduct to come forward, including whistleblowers and former employees [7].

NEW YORK, Dec. 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.So what: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...